Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, People's Republic of China.
Med Oncol. 2012 Sep;29(3):1964-71. doi: 10.1007/s12032-011-0051-5. Epub 2011 Aug 28.
As a main effector in the renin-angiotensin system, the angiotensin II plays a critical role in cell proliferation and angiogenesis. The change between angiotensin II and its precursor is conducted by the angiotensin-converting enzyme. The association between angiotensin-converting enzyme insertion/deletion polymorphism and the activity of angiotensin-converting enzyme was testified. Furthermore, previous researches proved the association between angiotensin-converting enzyme activity and the risk of prostate cancer. Therefore, we conducted a case-control study in the Han population of China to elaborate the relation between the angiotensin-converting enzyme insertion/deletion polymorphism and prostate cancer. DNA was extracted from blood samples collected from 189 pathologically diagnosed prostate cancer patients and 290 cancer-free subjects. The angiotensin-converting enzyme insertion/deletion genotype was determined by polymerase chain reaction analysis. Stratified analyses on age (<71 or ≥ 71), cancer stage (localized or advanced), Gleason score (<7 or ≥ 7) and PSA level (<20 ng/ml or ≥ 20 ng/ml) were performed. We found the II genotype (OR = 0.304 95%CI (0.180,0.515), P < 0.001) and I allele (OR = 0.547 95%CI(0.421,0.711), P < 0.001) were associated with a decreased risk of prostate cancer compared with the DD genotype and D allele. The DD genotype was related to patients with aggressive stage of prostate cancer (OR = 2.214 95%CI(1.169, 4.194), P = 0.014) and patients diagnosed of prostate cancer at a relatively early age (OR = 0.513 95%CI(0.272, 0.965), P = 0.037). The results of our experiment supported the hypothesis that the angiotensin-converting enzyme insertion/deletion polymorphism, a potential risk factor in carcinogenesis, played an important role in the Han population of China.
作为肾素-血管紧张素系统的主要效应物，血管紧张素 II 在细胞增殖和血管生成中起着关键作用。血管紧张素 II 与其前体之间的转换由血管紧张素转换酶进行。已经证明了血管紧张素转换酶插入/缺失多态性与血管紧张素转换酶活性之间的关联。此外，先前的研究证明了血管紧张素转换酶活性与前列腺癌风险之间的关联。因此，我们在中国汉族人群中进行了一项病例对照研究，以阐述血管紧张素转换酶插入/缺失多态性与前列腺癌之间的关系。从 189 例经病理诊断的前列腺癌患者和 290 例无癌对照者的血液样本中提取 DNA。通过聚合酶链反应分析确定血管紧张素转换酶插入/缺失基因型。对年龄（<71 岁或≥71 岁）、癌症分期（局限性或晚期）、Gleason 评分（<7 或≥7）和 PSA 水平（<20ng/ml 或≥20ng/ml）进行分层分析。我们发现与 DD 基因型和 D 等位基因相比，II 基因型（OR=0.304 95%CI（0.180,0.515），P<0.001）和 I 等位基因（OR=0.547 95%CI（0.421,0.711），P<0.001）与前列腺癌风险降低相关。DD 基因型与前列腺癌侵袭性分期的患者（OR=2.214 95%CI（1.169,4.194），P=0.014）和相对较早被诊断为前列腺癌的患者（OR=0.513 95%CI（0.272,0.965），P=0.037）相关。我们的实验结果支持这样的假设，即血管紧张素转换酶插入/缺失多态性作为潜在的致癌因素，在中国汉族人群中起着重要作用。
